Healthequity (HQY) Cash & Equivalents (2013 - 2026)

Healthequity has reported Cash & Equivalents for 14 years, with the latest figure at $256.0 million in Q3 2026.

• On a quarterly basis, Cash & Equivalents fell 15.92% year-over-year to $256.0 million in Q3 2026; TTM through Jul 2026 was $256.0 million, a 15.92% decrease from a year earlier, with the FY2026 full-year figure at $318.9 million, up 7.76% from the prior year.
• Cash & Equivalents was $256.0 million for Q3 2026 at Healthequity, down from $265.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $404.0 million in Q1 2024, with the low at $161.2 million in Q2 2022.
• Average Cash & Equivalents over 5 years is $274.7 million, with a median of $287.9 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 78.11% in 2022, then soared 64.14% in 2023.
• Over 5 years, Cash & Equivalents stood at $210.2 million in 2022, then surged by 58.93% to $334.1 million in 2023, then decreased by 3.56% to $322.2 million in 2024, then fell by 4.01% to $309.3 million in 2025, then dropped by 17.22% to $256.0 million in 2026.
• The last three Cash & Equivalents figures came in at $256.0 million (Q3 2026), $265.4 million (Q2 2026), and $318.9 million (Q1 2026), per Business Quant data.